Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment

(2020) Hossein Poustchi et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Emerging coronaviruses: Genome structure, replication, and pathogenesis

(2020) Yu Chen et al.   JOURNAL OF MEDICAL VIROLOGY

Radiologic Management of COVID-19: Preliminary Experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)

(2020) Arash Mahdavi et al.   Iranian Journal of Radiology

Virological assessment of hospitalized patients with COVID-2019

(2020) Roman Wölfel et al.   NATURE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

(2020) Wei Tang et al.   BMJ-British Medical Journal

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

(2020) Shufa Zheng et al.   BMJ-British Medical Journal

Viral dynamics in mild and severe cases of COVID-19

(2020) Yang Liu et al.   LANCET INFECTIOUS DISEASES

Understanding COVID-19: what does viral RNA load really mean?

(2020) Gavin M Joynt et al.   LANCET INFECTIOUS DISEASES

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

(2019) Caroline S. de Freitas et al.   PLoS Neglected Tropical Diseases

Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child

(2019) Jolien J. M. Freriksen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication

(2018) André C. Ferreira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

(2017) Mark S. Sulkowski et al.   Hepatology International

Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses

(2017) Abdo A. Elfiky et al.   JOURNAL OF MEDICAL VIROLOGY

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

(2015) Brian J. Kirby et al.   CLINICAL PHARMACOKINETICS

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1

(2014) Namiki Izumi et al.   ANTIVIRAL THERAPY

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

(2014) Christophe Hézode et al.   GUT

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

(2013) Eric Lawitz et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

(2012) Maribel Rodriguez-Torres et al.   JOURNAL OF HEPATOLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY